The purpose of this study is to evaluate diagnostic performance of piflufolastat F 18 PET/CT in the staging of patients suspected of having, or who are at high risk for, metastatic ccRCC and its impact on intended clinical management.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
United States (Nationwide)
Jennifer Schroeder
Radiology-Molecular Imaging and Therapeutics
Clinical or Medical
Interventional
Cancer (Kidney)
25-0975
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
